Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients.

Lee MH, Huang CF, Lai HC, Lin CY, Dai CY, Liu CJ, Wang JH, Huang JF, Su WP, Yang HC, Kee KM, Yeh ML, Chuang PH, Hsu SJ, Huang CI, Kao JT, Chen CC, Chen SH, Jeng WJ, Yang HI, Yuan Y, Lu SN, Sheen IS, Liu CH, Peng CY, Kao JH, Yu ML, Chuang WL, Chen CJ.

Sci Rep. 2017 Jun 16;7(1):3718. doi: 10.1038/s41598-017-02313-y.

2.

Perioperative plasma glypican-3 level may enable prediction of the risk of recurrence after surgery in patients with stage I hepatocellular carcinoma.

Ofuji K, Saito K, Suzuki S, Shimomura M, Shirakawa H, Nobuoka D, Sawada Y, Yoshimura M, Tsuchiya N, Takahashi M, Yoshikawa T, Tada Y, Konishi M, Takahashi S, Gotohda N, Nakamoto Y, Nakatsura T.

Oncotarget. 2017 Jun 6;8(23):37835-37844. doi: 10.18632/oncotarget.14271.

3.

Optimizing Surveillance Performance of Alpha-Fetoprotein by Selection of Proper Target Population in Chronic Hepatitis B.

Chung JW, Kim BH, Lee CS, Kim GH, Sohn HR, Min BY, Song JC, Park HK, Jang ES, Yoon H, Kim J, Shin CM, Park YS, Hwang JH, Jeong SH, Kim N, Lee DH, Lee J, Ahn S, Kim JW.

PLoS One. 2016 Dec 20;11(12):e0168189. doi: 10.1371/journal.pone.0168189. eCollection 2016.

4.

Serum Adiponectin, Vitamin D, and Alpha-Fetoprotein in Children with Chronic Hepatitis C: Can They Predict Treatment Response?

Khedr MA, Sira AM, Saber MA, Raia GY.

Int J Hepatol. 2015;2015:617623. doi: 10.1155/2015/617623. Epub 2015 Nov 10.

5.

Alpha-fetoprotein before and after pegylated interferon therapy for predicting hepatocellular carcinoma development.

Takeuchi Y, Ikeda F, Osawa T, Araki Y, Takaguchi K, Morimoto Y, Hashimoto N, Sakaguchi K, Sakata T, Ando M, Makino Y, Matsumura S, Takayama H, Seki H, Nanba S, Moritou Y, Yasunaka T, Ohnishi H, Takaki A, Nouso K, Iwasaki Y, Yamamoto K.

World J Hepatol. 2015 Sep 8;7(19):2220-8. doi: 10.4254/wjh.v7.i19.2220.

6.

Targeted proteomics for biomarker discovery and validation of hepatocellular carcinoma in hepatitis C infected patients.

Mustafa GM, Larry D, Petersen JR, Elferink CJ.

World J Hepatol. 2015 Jun 8;7(10):1312-24. doi: 10.4254/wjh.v7.i10.1312. Review.

7.

Telomerase inhibition decreases alpha-fetoprotein expression and secretion by hepatocellular carcinoma cell lines: in vitro and in vivo study.

Tahtouh R, Azzi AS, Alaaeddine N, Chamat S, Bouharoun-Tayoun H, Wardi L, Raad I, Sarkis R, Antoun NA, Hilal G.

PLoS One. 2015 Mar 30;10(3):e0119512. doi: 10.1371/journal.pone.0119512. eCollection 2015.

8.

Differentiating hepatocellular carcinoma from hepatitis C using metabolite profiling.

Wei S, Suryani Y, Gowda GA, Skill N, Maluccio M, Raftery D.

Metabolites. 2012 Oct 10;2(4):701-16. doi: 10.3390/metabo2040701.

9.

Surveillance for early diagnosis of hepatocellular carcinoma: how best to do it?

Giannini EG, Cucchetti A, Erroi V, Garuti F, Odaldi F, Trevisani F.

World J Gastroenterol. 2013 Dec 21;19(47):8808-21. doi: 10.3748/wjg.v19.i47.8808. Review.

10.

Increased α-Fetoprotein Predicts Steatosis among Patients with Chronic Hepatitis C Genotype 4.

Mousa N, Gad Y, Abdel-Aziz A, Abd-Elaal I.

Int J Hepatol. 2012;2012:636392. doi: 10.1155/2012/636392. Epub 2012 May 14.

11.

Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C.

Sterling RK, Wright EC, Morgan TR, Seeff LB, Hoefs JC, Di Bisceglie AM, Dienstag JL, Lok AS.

Am J Gastroenterol. 2012 Jan;107(1):64-74. doi: 10.1038/ajg.2011.312. Epub 2011 Sep 20.

12.

A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma.

Abu Dayyeh BK, Yang M, Fuchs BC, Karl DL, Yamada S, Sninsky JJ, O'Brien TR, Dienstag JL, Tanabe KK, Chung RT; HALT-C Trial Group.

Gastroenterology. 2011 Jul;141(1):141-9. doi: 10.1053/j.gastro.2011.03.045. Epub 2011 Mar 24.

13.

Surveillance for hepatocellular carcinoma: in whom and how?

El-Serag HB, Davila JA.

Therap Adv Gastroenterol. 2011 Jan;4(1):5-10. doi: 10.1177/1756283X10385964. No abstract available.

14.

Male-like sexual behavior of female mouse lacking fucose mutarotase.

Park D, Choi D, Lee J, Lim DS, Park C.

BMC Genet. 2010 Jul 7;11:62. doi: 10.1186/1471-2156-11-62.

15.

Antibody Arrays Identify Potential Diagnostic Markers of Hepatocellular Carcinoma.

Sun H, Chua MS, Yang D, Tsalenko A, Peter BJ, So S.

Biomark Insights. 2008 Jan 21;3:1-18.

16.

AFP-specific CD4+ helper T-cell responses in healthy donors and HCC patients.

Evdokimova VN, Liu Y, Potter DM, Butterfield LH.

J Immunother. 2007 May-Jun;30(4):425-37.

17.

Low utility of plasma Nociceptin/orphanin FQ in the diagnosis of hepatocellular carcinoma.

Spadaro A, Ajello A, Luigiano C, Morace C, Resta ML, Berlinghieri G, Campo S, Scisca C, Alibrandi A, D'Arrigo G, Alessi N, Ferrau O, Freni MA.

World J Gastroenterol. 2006 Aug 7;12(29):4716-20.

18.

Expression of AFP and Rev-Erb A/Rev-Erb B and N-CoR in fetal rat liver, liver injury and liver regeneration.

Meier V, Tron K, Batusic D, Elmaouhoub A, Ramadori G.

Comp Hepatol. 2006 Jul 5;5:2.

19.

Clinical Profiles of Chronic Hepatitis C in a Major County Medical Center Outpatient Setting in United States.

Hu KQ, Yang H, Lin YC, Lindsay KL, Redeker AG.

Int J Med Sci. 2004;1(2):92-100. Epub 2004 Jun 1.

Supplemental Content

Support Center